Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-005 in Triple Negative Breast Cancer
NCT03316794Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jan 2018
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SC-005 in triple-negative breast cancer (TNBC), sponsored by AbbVie Inc. Primary endpoint: Number of Participants with Dose-limiting Toxicities at 21 days. Started Jan 2018; status: terminated.
02
Drugs
SC-005
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03316794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316794.